Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-01-12
2010-12-14
Olson, Eric S (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S017900
Reexamination Certificate
active
07851451
ABSTRACT:
The invention provides formulations and methods for mediating inflammation, in particular an inflammatory bowel disorder such as necrotizing enterocolitis, and for. Further, the formulations are effective in lowering blood cholesterol and decreasing blood cholesterol absorption. The formulations comprise at least one ganglioside, which may be selected from the group consisting of: GD3, GM1, GM2, GM3, and GD1b. The invention provides a method of treating or preventing inflammatory diseases, such as necrotizing enterocolitis by delivery of at least one ganglioside to a subject in need thereof. Supplementation of foods or liquids with gangliosides, fore example infant formula or infant foods, can be employed according to the invention.
REFERENCES:
patent: 4762822 (1988-08-01), Ettinger
patent: 5190925 (1993-03-01), della Valle et al.
patent: 5281702 (1994-01-01), Tubaro et al.
patent: 6998392 (2006-02-01), Clandinin et al.
patent: 2004/0047856 (2004-03-01), Williams et al.
patent: 2005/0107311 (2005-05-01), Berger et al.
patent: 2006/0276430 (2006-12-01), Clandinin
patent: 2007/0173480 (2007-07-01), Clandinin et al.
patent: 2010/0136023 (2010-06-01), Williams et al.
patent: 0351784 (1990-01-01), None
patent: 1323424 (2003-07-01), None
patent: 2289274 (1995-11-01), None
patent: 62145015 (1987-06-01), None
patent: 1163125 (1989-06-01), None
patent: 9009185 (1993-08-01), None
patent: 9520959 (1995-08-01), None
patent: 9605844 (1996-02-01), None
patent: WO02/40051 (2002-03-01), None
patent: 0240051 (2002-05-01), None
patent: 0245740 (2002-06-01), None
The Merck Manual of Diagnosis and Therapy, Seventeenth Edition, published 1999 by Merck Research laboratories, pp. 2195-2196.
Merriam-Webster's Collegiate Dictionary, published 1998 by Merriam-Webster, Incorporated, p. 924.
Martin et al., “Bovine Milk Gangliosides: Changes in Ceramide Moiety with Stage of Lactation” Lipids (2001) vol. 36 No. 1, pp. 291-298.
Bucolo et al., “Effects of Mipragoside on Ocular Allergic Inflammation in the Rabbit”, Journal of Ocular Pharmacology, vol. 9, No. 4, 1993, pp. 321-332.
Oliveira et al., GM-1 Ganglioside Treatment Reduces Motoneuron Death After Ventral Root Avulsion in Adult Rats, Neuroscience Letters, vol. 293, No. 2, p. 131, Abstract.
Derwent Abstract, XP-002286617 & JP 01 163125.
Sugimoto, et al., “Total Synthesis of gangliosides GM1 and GM2”, Carbohydrate Research, vol. 156, 1986, pp. C1-C5, XP001053330.
Colarow et al., “Characterization and biological activity of gangliosides in buffalo milk”, Biochimica et Biophysica Acta 1631, 2003, pp. 94-106.
Pan et al., “Variation of the ganglioside compositions of human milk, cow's milk, and infant formulas”, Early Human Development, vol. 57, 2000, pp. 25-31.
Puente et al., “Gangliosides in Bovine Milk”, Biol. Chem. Hoppe-Seyler, vol. 373, May 1992, pp. 283-288.
Machine translation of DE4430041, translated online at v3.espacenet.com.
The Merck Manual of Diagnosis and Therapy, Seventeenth Edition, published 1999 by Merck Research Laboratories, pp. 283-286, 1249-1250, and 2084.
Alonso et al., “Dissociation of the Effects of the Antitumour Ether Lipid ET-18-OCH3 on Cytosolic Calcium and on Apoptosis”, Brit. J. Pharmacol. 121 (1997) 1364-1368.
Anderson et al., “Essential Fatty Acid Deficiency and Renewal of Rod Outer Segments in the Albino Rat”, Invest Ophthalmol. 15, 232-236 (1976).
Anderson, “The Caveolae Membrane System”, Annual Review of Biochemistry; 1998;67:199-225.
Andersson et al., “Rates of Cholesterol, Ubiquinone, Dolichol and Doclichyl-P Biosynthesis in Rat Brain Slices”, FEBS Lett 1990;269:15-8.
Asou et al., “Changes in Ganglioside Composition and Morphological Features During the Development of Cultured Astrocytes From Rat Brain”, Neurosci. Res. 6 (1989) 369-375.
Aydin et al., “Age-Related Changes in GM1, GD1a, GT1b Components of Gangliosides in Wistar Albino Rats”, Cell Biochem Funct 2000;18:41-5.
Barbour et al., “Glycolipid Depletion Using a Ceramide Analogue (PDMP) Alters Growth, Adhesion, and Membrane Lipid Organization in . . . ”, J. Cell. Physiol. 150, 610-619 (1992).
Basavarajappa et al., “Activation of Arachidonic Acid-Specific Phospholipase A2 in Human Neuroblastoma Cells after . . . ”, Clin. Exp. Res. 21 (1997) 1199-1203.
Bastiaanse et al., “The Effect of Membrane Cholesterol Content on Ion Transport Processes in Plasma Membranes”, Cardiovasc Res 1997;33:272-83.
Bauldry et al., “Phospholipase A2 Activation in Human Neutrophils”, J. Biol. Chem. 263 (1988) 16787-16795.
Bauldry et al., Differential Actions of Diacyl- and Alkylacylglycerols in Priming Phospholipase A2, 5-Lipoxygenase . . . , Biochim. Biophys. Acta 1084 (1991) 178-184.
Bavari et al., “Lipid Raft Microdomains: A Gateway for Compartmentalized Trafficking of Ebola and Marburg Viruses”, J Exp Med 2002;195(5):593-602.
Belosevic et al., “Giardia muris: Correlation Between Oral Dosage, Course of Infection, and Trophozoite Distribution in the Mouse . . . ”, 1983. Exp. Parasitol. 56:93-100.
Bernett et al., “Determination of Serum Phospholipid Metabolic Profiles by High-Performance Liquid Chromatography”, J. Liq. Chromatogr. 8 (1985) 1573-1591.
Berger et al., “Nutritional Implications of Replacing Bovine Milk Fat With Vegetable Oil in Infant Formulas”, J. Pediatr. Gastroenterol. Nutr. 30 (2000) 115-130.
Birch et al., “Visual Acuity and the Essentiality of Docosahexaenoic Acid and Arachidonic Acid in the Diet of Term Infants”, Pediatr. Res. 44, 201-209 (1998).
Bittman et al., “Influence of Cholesterol on Bilayers of Ester-and Ether-Linked Phospholipis”, Biochim. Biophys. Acta 772 (1984) 117-126.
Blank et al., “Meats and Fish Consumed in the American Diet Contain Substantial Amounts of Ether-Linked Phospholipids”, J. Nutr. 122 (1992) 1656-1661.
Bouhours et al., “Developmental Changes of Hematoside of Rat Small Intestine”, J. Biol. Chem. 258 (1983) 299-304.
Brown et al., “Sorting of GPI-Anchored Proteins to Glycolipid-Enriched Membrane Subdomains During Transport to the Apical Cell Surface”, 1992. Cell. 68:533-544.
Brown et al., “Functions of Lipid Rafts in Biological Membranes”, Annu Rev Cell Dev Biol 1998;14:111-36.
Buret et al., “Growth, Activities of Enzymes in the Small Intestine, and Ultrastructure of Microvillous Border in Gerbils . . . ”, 1991. Parasitol Res. 77:109-114.
Byrne et al., “Ganglioside-Induced Neuritogenesis: Verification That Ganglioside Are the Active Agents, and Comparison of Molecular Species”, J. Neurochem. 41 (1983) 1214-122.
Carlson, “N-Acetylneuraminic Acid Concentrations in Human Milk Oligosaccharides and Glycoproteins During Lactation”, Am J Clin Nutr 1985;41:720-6.
Carlson et al., “Visual Acuity and Fatty Acid Status of Term Infants Fed Human Milk and Formulas With and Without Docosahexaenoate and . . . ”, Pediatr. Res. 39, 882-888 (1996).
Carrie et al., “Docosahexaenoic Acid-Rich Phospholipid Supplementation”, Nutr. Neurosci. 5, 43-52 (2002).
Chen et al., “Sphingomyelin Content of Intestinal Cell Membranes Regulates Cholesterol Absorption”, Biochem J 1992;286 ( Pt 3):771-777.
Christiansen et al., “Microvillus Membrane Vesicles From Pig Small Intestine”, Biochim. Biophys. Acta 647 (1981) 188-195.
Clandinin et al., “Effects of Methionine Supplementation on the Incidence of Dietary Fat Induced Myocardial Lesions in the Rat”, J. Nutr. 110 (1980) 1197-203.
Clandinin et al., “Dietary Fat: Exogenous Determination of Membrane Structure and Cell Function”, FASEB J 1991;5:2761-9.
Daniels et al., “Disaccharidase Activity in Male and Female C57BL/6 Mice Infected with Giardia Muris”, 1995. Parasitol Res. 81:143-147.
Danielsen et al., “A Transferrin-Like GPI-linke
Clandinin Michael Thomas
Park Eek Joong
Duane Morris LLP
Gould Robert M.
MTI Meta Tech Inc.
Olson Eric S
LandOfFree
Formulations for mediating inflammatory bowel disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Formulations for mediating inflammatory bowel disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Formulations for mediating inflammatory bowel disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4166626